Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable HNSCC
NCT07465276Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2026
- Primary completion
- Apr 2028
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ficerafusp alfa in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Dana-Farber Cancer Institute. Started Mar 2026; status: recruiting.
02
Drugs
ficerafusp alfa
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT07465276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07465276.